For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...
The FDA is weighing the regulatory fate of Insmed’s DPP1 inhibitor brensocatib for bronchiectasis. An approval for the oral small-molecule protease inhibitor would provide a much-needed targeted ...
Add Yahoo as a preferred source to see more of our stories on Google. Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 ...
Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...
Miami (July 31, 2025) – The Bronchiectasis and NTM Association joins other global patient advocacy organizations, professional societies, and lung health experts for the third annual World NTM ...
Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of ...
Please provide your email address to receive an email when new articles are posted on . Patients in this subgroup participated in the phase 3 ASPEN trial. Brensocatib given as 10 mg or 25 mg performed ...
WASHINGTON, July 1, 2025 /PRNewswire/ -- Today, on World Bronchiectasis Day, the American Lung Association is launching a new campaign to support people living with bronchiectasis, which is a chronic ...
If you have non-cystic fibrosis bronchiectasis, you’re likely an expert on the “lung side” of the disease — the stubborn mucus, the nagging cough, and the constant threat of a flare-up. But by causing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results